Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential

References

• WHO. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
   Google Scholar
• APA. Diagnostic and statistical manual of mental disorders. 4th ed. Text Revision, Washington, DC: American Psychiatric Publishing; 2000.
   Google Scholar
• APA. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
   Google Scholar
• Gowing LR, Ali RL, Allsop S, et al. Global statistics on addictive behaviours: 2014 status report. Addiction. 2015;110:904–919.
   PubMed Web of Science ®Google Scholar
• WHO. Global status report on alcohol and health. Geneva, Switzerland: World Health Organization; 2011.
   Google Scholar
• Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet. 2013 [Nov 9];382:1575–1586.
   PubMed Web of Science ®Google Scholar
• Grant BF, Stinson FS, Dawson DA, et al. Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61:361–368.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62:617–627.
   PubMed Web of Science ®Google Scholar
• Pirkola SP, Poikolainen K, Lonnqvist JK. Currently active and remitted alcohol dependence in a nationwide adult general population–results from the Finnish health 2000 study. Alcohol Alcohol. 2006 May-Jun;41:315–320.
   PubMed Web of Science ®Google Scholar
• Rehm J, Room R, Van Den Brink W, et al. Alcohol use disorders in EU countries and Norway: an overview of the epidemiology. Eur Neuropsychopharmacol. 2005;15:377–388.
   PubMed Web of Science ®Google Scholar
• Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry. 2015 [Aug 1];72:757–766.
   PubMed Web of Science ®Google Scholar
• Connor JP, Haber PS, Hall WD. Alcohol use disorders. The Lancet. 2015. pii: S0140-6736(15)00122-1. doi:10.1016/S0140-6736(15)00122-1. [Epub ahead of print]
   Google Scholar
• Berglund M, Thelander S, Jonsson E. Treating alcohol and drug abuse: an evidence based review. Weinheim: Wiley-VCH; 2003.
   Google Scholar
• Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs. 2009 Jul;70:516–527.
   PubMed Web of Science ®Google Scholar
• Prendergast M, Podus D, Finney J, et al. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006;101:1546–1560.
   PubMed Web of Science ®Google Scholar
• Soyka M, Kranzler HR, Berglund M, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 1: alcoholism. World J Biol Psychiatry. 2008;9:6–23.
   PubMed Web of Science ®Google Scholar
• Miller WR, Wilbourne PL. Mesa grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction. 2002 Mar;97:265–277.
   PubMed Web of Science ®Google Scholar
• Hester RK, Miller WR. Handbook of alcoholism treatment approaches: effective alternatives. Boston: Allyn & Bacon; 1995.
   Google Scholar
• Project MATCH Research Group. Project MATCH secondary a priori hypotheses. Addiction. 1997 Dec;92:1671–1698.
   PubMed Web of Science ®Google Scholar
• Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006 Sep;111:855–876.
   PubMed Web of Science ®Google Scholar
• Soyka M, Rosner S. Emerging drugs to treat alcoholism. Expert Opin Emerg Drugs. 2010 [Jun 19];15:695–711.
   PubMed Web of Science ®Google Scholar
• Spanagel R, Kiefer F. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci. 2008 Mar;29:109–115.
   PubMed Web of Science ®Google Scholar
• Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. Jama, 2014 [May 14];311:1889–1900.
   PubMed Web of Science ®Google Scholar
• Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?. Addiction. 2013;108:275–293.
   PubMed Web of Science ®Google Scholar
• Rosner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;CD004332. doi:10.1002/14651858.CD004332.pub2
   Google Scholar
• Littleton J, Zieglgansberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict. 2003;12(Suppl 1):S3–11.
   PubMed Web of Science ®Google Scholar
• Donoghue K, Elzerbi C, Saunders R, et al. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction. 2015;110:920–930.
   PubMed Web of Science ®Google Scholar
• Muller CA, Geisel O, Banas R, et al. Current pharmacological treatment approaches for alcohol dependence. Expert Opin Pharmacother. 2014;15:471–481.
   PubMed Web of Science ®Google Scholar
• Muller CA, Geisel O, Pelz P, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): A randomized, placebo-controlled trial. Eur Neuropsychopharmacology: Journal Eur Coll Neuropsychopharmacol. 2015;25:1167–1177.
   PubMed Web of Science ®Google Scholar
• Davies DL, Bortolato M, Finn DA, et al. Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. Alcohol Clin Exp Res. 2013;37:8–15.
   PubMed Web of Science ®Google Scholar
• Spanagel R, Vengeliene V. New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci. 2013;13:583–609.
   PubMedGoogle Scholar
• Nutt DJ. The role of the opioid system in alcohol dependence. J Psychopharmacology. 2014 Jan;28:8–22.
   PubMed Web of Science ®Google Scholar
• Ciccocioppo R, Martin-Fardon R, Weiss F. Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacology. 2002 Sep;27:391–399.
   PubMed Web of Science ®Google Scholar
• Cowen MS, Lawrence AJ. The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psychiatry. 1999 Oct;23:1171–1212.
   PubMed Web of Science ®Google Scholar
• Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem. 2004;4:39–50.
   PubMed Web of Science ®Google Scholar
• Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl). 1997 Jan;129:99–111.
   PubMed Web of Science ®Google Scholar
• Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992 May;13:177–184.
   PubMed Web of Science ®Google Scholar
• Oswald LM, Wand GS. Opioids and alcoholism. Physiol Behav. 2004 Apr;81:339–358.
   PubMed Web of Science ®Google Scholar
• Bjork K, Terasmaa A, Sun H, et al. Ethanol-induced activation of AKT and DARPP-32 in the mouse striatum mediated by opioid receptors. Addict Biol. 2010;15(3):299–303.
   PubMed Web of Science ®Google Scholar
• Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev. 2009 Apr;89:649–705.
   PubMed Web of Science ®Google Scholar
• Vengeliene V, Celerier E, Chaskiel L, et al. Compulsive alcohol drinking in rodents. Addict Biol. 2009;14:384–396.
   PubMed Web of Science ®Google Scholar
• Adcock RA, Thangavel A, Whitfield-Gabrieli S, et al. Reward-motivated learning: mesolimbic activation precedes memory formation. Neuron. 2006 [May 4];50:507–517.
   PubMed Web of Science ®Google Scholar
• Bencherif B, Wand GS, McCaul ME, et al. Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry. 2004 [Feb 1];55:255–262.
   PubMed Web of Science ®Google Scholar
• Heinz A, Reimold M, Wrase J, et al. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry. 2005;62:57–64.
   PubMed Web of Science ®Google Scholar
• Williams TM, Davies SJ, Taylor LG, et al. Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study. Eur Neuropsychopharmacol. 2009;19:740–748.
   PubMed Web of Science ®Google Scholar
• Clapp P, Bhave SV, Hoffman PL. How adaptation of the brain to alcohol leads to dependence: a pharmacological perspective. Alcohol Res Health. 2008;31:310–339.
   PubMedGoogle Scholar
• Bart G, Schluger JH, Borg L, et al. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology. 2005;30:2254–2262.
   PubMed Web of Science ®Google Scholar
• Michel ME, Bolger G, Weissman BA. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol. 1985 Apr;7:175–177.
   PubMed Web of Science ®Google Scholar
• Walker BM, Koob GF. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology. 2008 Feb;33:643–652.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56:719–724.
   PubMed Web of Science ®Google Scholar
• Emmerson PJ, Liu MR, Woods JH, et al. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther. 1994;271:1630–1637.
   PubMed Web of Science ®Google Scholar
• Ingman K, Hagelberg N, Aalto S, et al. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology. 2005;30:2245–2253.
   PubMed Web of Science ®Google Scholar
• Dixon R, Gentile J, Hsu HB, et al. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol. 1987;27:233–239.
   PubMed Web of Science ®Google Scholar
• Gal TJ, DiFazio CA, Dixon R. Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther. 1986 Nov;40:537–542.
   PubMed Web of Science ®Google Scholar
• Osborn MD, Lowery JJ, Skorput AG, et al. In vivo characterization of the opioid antagonist nalmefene in mice. Life Sci. 2010 Apr 10;86:624–630.
   PubMed Web of Science ®Google Scholar
• Brokso Kyhl L-E, Li S, Faerch KU, et al. Population pharmacokinetics of nalmefene in healthy subjects and its relation to mu-opioid receptor occupancy. Br J Clin Pharmacol. 2015 Oct 19. doi:10.1111/bcp.12805. [Epub ahead of print]
   Google Scholar
• Kim S, Wagner HN Jr., Villemagne VL, et al. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. J Nucl Med. 1997;38:1726–1731.
   PubMed Web of Science ®Google Scholar
• June HL, Grey C, Warren-Reese C, et al. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res. 1998;22:2174–2185.
   PubMed Web of Science ®Google Scholar
• Drobes DJ, Anton RF, Thomas SE, et al. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res. 2004;28:1362–1370.
   PubMed Web of Science ®Google Scholar
• Drobes DJ, Anton RF, Thomas SE, et al. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology. 2003;28:755–764.
   PubMed Web of Science ®Google Scholar
• Anton RF, Pettinati H, Zweben A, et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24:421–428.
   PubMed Web of Science ®Google Scholar
• Gual A, He Y, Torup L, et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013 Nov;23:1432–1442.
   PubMed Web of Science ®Google Scholar
• Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res, 2007 [Jul];31:1179–1187.
   PubMed Web of Science ®Google Scholar
• Mann K, Bladstrom A, Torup L, et al. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry, 2013 [Apr 15];73:706–713.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994;18:1162–1167.
   PubMed Web of Science ®Google Scholar
• Van Den Brink W, Sorensen P, Torup L, et al. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. J Psychopharmacol. 2014;28:733–744.
   PubMed Web of Science ®Google Scholar
• World Health Organization. International Guide for Monitoring Alcohol Consumption and Related Harm. 2000
   Google Scholar
• Aubin H-J, Reimer J, Nutt DJ, et al. Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients. Eur Addict Res. 2015;21:160–168.
   PubMed Web of Science ®Google Scholar
• Matz J, Graff C, Vainio PJ, et al. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study. Clin Drug Investig. 2011 [Nov 1];31:799–811.
   PubMed Web of Science ®Google Scholar
• Lotsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy?. Trends Mol Med. 2005 Feb;11:82–89.
   PubMed Web of Science ®Google Scholar
• Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007 Mar;81:429–444.
   PubMed Web of Science ®Google Scholar
• Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998 [Aug 4];95:9608–9613.
   PubMed Web of Science ®Google Scholar
• Bilbao A, Robinson JE, Heilig M, et al. A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice. Biol Psychiatry. 2015 [May 15];77:850–858.
   PubMed Web of Science ®Google Scholar
• Setiawan E, Pihl RO, Benkelfat C, et al. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. Pharmacogenomics. 2012;13:1161–1172.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Armeli S, Covault J, et al. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. Addict Biol. 2013 Jan;18:193–201.
   PubMed Web of Science ®Google Scholar
• Chamorro A-J, Marcos M, Miron-Canelo J-A, et al. Association of micro-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol. 2012;17:505–512.
   PubMed Web of Science ®Google Scholar
• Chen D, Liu L, Xiao Y, et al. Ethnic-specific meta-analyses of association between the OPRM1 A118G polymorphism and alcohol dependence among Asians and Caucasians. Drug Alcohol Depend. 2012 [Jun 1];123:1–6.
   PubMed Web of Science ®Google Scholar
• Arias AJ, Armeli S, Gelernter J, et al. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res. 2008;32:1159–1166.
   PubMed Web of Science ®Google Scholar
• Van Den Brink W, Aubin H-J, Bladstrom A, et al. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol. 2013 Sep-Oct;48:570–578.
   PubMed Web of Science ®Google Scholar
• Van Den Brink W, Strang J, Gual A, et al. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Expert Opin Drug Saf. 2015 Apr;14:495–504.
   PubMed Web of Science ®Google Scholar
• Roerecke M, Gual A, Rehm J. Reduction of alcohol consumption and subsequent mortality in alcohol use disorders: systematic review and meta-analyses. J Clin Psychiatry. 2013 Dec;74:e1181–9.
   PubMed Web of Science ®Google Scholar
• Roerecke M, Sorensen P, Laramee P, et al. Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality risk. J Psychopharmacol. 2015;29:1152–1158.
   PubMed Web of Science ®Google Scholar
• Francois C, Rahhali N, Chalem Y, et al. The effects of as-needed nalmefene on patient-reported outcomes and quality of life in relation to a reduction in alcohol consumption in alcohol-dependent patients. PLoS One. 2015;10:e0129289.
   Google Scholar
• Soyka M, Friede M, Schnitker J. Comparing nalmefene and naltrexone in alcohol dependence: are there any differences? Results from an indirect meta-analysis. Pharmacopsychiatry. 2016 Feb 4. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Garbutt JC, Greenblatt AM, West SL, et al. Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction. 2014;109:1274–1284.
   PubMed Web of Science ®Google Scholar
• Roche DJ, King AC. Sex differences in acute hormonal and subjective response to naltrexone: The impact of menstrual cycle phase. Psychoneuroendocrinology. 2015 Feb;52:59–71.
   PubMed Web of Science ®Google Scholar
• Agabio R, Pani PP, Preti A, et al. Efficacy of medications approved for the treatment of alcohol dependence and alcohol withdrawal syndrome in female patients: a descriptive review. Eur Addict Res. 2016;22:1–16.
   PubMedGoogle Scholar
• Stevenson M, Pandor A, Stevens JW, et al. Nalmefene for reducing alcohol consumption in people with alcohol dependence: an evidence review group perspective of a nice single technology appraisal. Pharmacoeconomics. 2015;33:833–847.
   PubMed Web of Science ®Google Scholar
• EMA. Selincro (nalmefene): summary of product characteristics. London: European Medicines Agency; 2014.
   Google Scholar
• Braillon A, Granger B. Nalmefene and alcohol dependence: A new approach or the same old unacceptable marketing?. Subst Abuse Rehabil. 2015;6:75–80.
   PubMedGoogle Scholar
• US NLM. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. 2015 [cited 10 November, 2015]; Available from: http://livertox.nih.gov/Nalmefene.htm
   Google Scholar
• Hernandez-Avila CA, Song C, Kuo L, et al. Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking. Alcohol Clin Exp Res. 2006;30:860–865.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Armeli S, Tennen H, et al. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol. 2003;23:294–304.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Tennen H, Penta C, et al. Targeted naltrexone treatment of early problem drinkers. Addict Behav. 1997;22:431–436.
   PubMed Web of Science ®Google Scholar
• Rosner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;CD001867. doi:10.1002/14651858.CD001867.pub2
   Google Scholar
• Aubin H-J, Daeppen J-B. Emerging pharmacotherapies for alcohol dependence: A systematic review focusing on reduction in consumption. Drug Alcohol Depend. 2013 [Jun 6];133:15–29.
   PubMed Web of Science ®Google Scholar
• Paille F, Martini H. Nalmefene: a new approach to the treatment of alcohol dependence. Subst Abuse Rehabil. 2014;5:87–94.
   PubMedGoogle Scholar
• Soyka M. Nalmefene for the treatment of alcohol dependence: a current update. Int J Neuropsychopharmacol. 2014 Apr;17:675–684.
   PubMed Web of Science ®Google Scholar
• Swift RM. Naltrexone and nalmefene: any meaningful difference?. Biol Psychiatry. 2013 [Apr 15];73:700–701.
   PubMed Web of Science ®Google Scholar
• Spence D. Bad medicine: nalmefene in alcohol misuse. Bmj. 2014;348:g1531.
   Google Scholar
• Penberthy JK, Hook JN, Vaughan MD, et al. Impact of motivational changes on drinking outcomes in pharmacobehavioral treatment for alcohol dependence. Alcohol Clin Exp Res. 2011;35:1694–1704.
   PubMed Web of Science ®Google Scholar
• Bujarski S, O’Malley SS, Lunny K, et al. The effects of drinking goal on treatment outcome for alcoholism. J Consult Clin Psychol. 2013;81:13–22.
   PubMed Web of Science ®Google Scholar